356 (PB344): Preclinical characterization of NTX-452, a potent, selective and highly efficacious WRN inhibitor for the treatment of MSI-H tumorsScott Boiko, Robert Svensson, Angela V. Toms et al.|European Journal of Cancer|2024Cited by 0